Optimal timing of recombinant herpes zoster virus vaccination for a JAK inhibitor treatment in rheumatoid arthritis: a multicentre, open-label, randomised comparative study (STOP-HZ study): study protocol
Authors:
- Satoshi TakanashiSTSatoshi Takanashi
- Koichiro OhmuraKOKoichiro Ohmura
- Kenta MisakiKMKenta Misaki
- Atsushi IhataAIAtsushi Ihata
- Toshihiro MatsuiTMToshihiro Matsui
- Shigeto TohmaSTShigeto Tohma
- Jun SaegusaJSJun Saegusa
- Shinji SatoSSShinji Sato
- Tsukasa MatsubaraTMTsukasa Matsubara
- Kunihiro YamaokaKYKunihiro Yamaoka
- Koichi AmanoKAKoichi Amano
- Toshiaki MiyamotoTMToshiaki Miyamoto
Open Access
Abstract
Introduction: Janus kinase (JAK) inhibitors are an important therapeutic option in the treatment of rheumatoid arthritis, but increase the risk of developing herpes zoster. Although a dry recombinant zoster vaccine (RZV) that can be used under immunosuppressive conditions has recently been developed, its optimal use and appropriate timing in patients scheduled to start JAK inhibitors is still unclear. The present study is designed to clarify the appropriate timing of JAK inhibitor initiation to measure varicella zoster virus (VZV)-specific IgG titers and VZV-specific T cell response in patients with rheumatoid arthritis who start tofacitinib at the first RZV vaccination or at the second one.Methods and analysis: STOP HZ (Effectiveness andSafeTyOfProphylactic RecombinantHerpesZoster Virus Vaccination for Rheumatoid Arthritis Patients with Tofacitinib Treatment) study is a multicentre, open-label, randomised, comparative study in patients with rheumatoid arthritis who are scheduled to start tofacitinib. This study enrols 60 study subjects in 12 sites. Enrolled subjects receive RZV two times on day 1 and week 8 and initiate tofacitinib 5 mg two times a day at the time of their first RZV (day 1, group A) or second RZV (week 8, group B) based on randomisation. The random assignment is performed centrally in a 1:1 ratio. Patients in Group B continue the same treatment until the start of tofacitinib treatment. Primary endpoint is VZV-specific IgG antibody titers at week 12 compared with those at baseline in each group. Secondary endpoints include comparison of VZV-specific IgG antibody between the groups, changes in disease activity of rheumatoid arthritis, VZV-specific T cell response and adverse events.Ethics and dissemination: The study has been approved by the Certified Review Board of Keio (No. 2022008), and conforms to the Declaration of Helsinki and good clinical practice guidelines. Written informed consent is obtained from participants prior to enrolment. The results of this study are planned to be submitted for publishment in relevant peer-review journals.Trial registration number: jRCTs031230329.Keywords
Funding Information
- Pfizer Japan (Grand Number N/A)
This publication has 14 references indexed in Scilit:
- Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinicianNature Reviews Rheumatology, 2024
- Rheumatoid Arthritis — Common Origins, Divergent MechanismsNew England Journal of Medicine, 2023
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 updateAnnals of the Rheumatic Diseases, 2022
- Impact of Janus kinase inhibitors on antibody response to 13-valent pneumococcal conjugate vaccine in patients with rheumatoid arthritisModern Rheumatology, 2022
- Safety of recombinant zoster vaccine: a retrospective study of 622 rheumatology patientsRheumatology, 2021
- CDAI and DAS28 in the management of rheumatoid arthritis in clinical practiceAnnals of the Rheumatic Diseases, 2020
- Burden of Herpes Zoster in the Japanese Population with Immunocompromised/Chronic Disease Conditions: Results from a Cohort Study Claims Database from 2005–2014Dermatology and Therapy, 2018
- Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for VaccinationArthritis & Rheumatology, 2016
- Measurement of Varicella‐Zoster Virus (VZV)–Specific Cell‐Mediated Immunity: Comparison between VZV Skin Test and Interferon‐γ Enzyme‐Linked Immunospot AssayThe Journal of Infectious Diseases, 2008
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988